Beckley Psytech Doses First Patients With Psilocin In Trial For Treatment Of Major Depression Disorder
The UK-based psychedelics medicine company Beckley Psytech announced Thursday that it has dosed its first patients in a Phase IIa study (NCT05434156) of ELE-101, a patent-protected synthetic formulation of psilocin benzoate to treat major depressive disorder (MDD). Psilocin is the active metabolite of psilocybin and ELE-101 has been specifically designed to provide consistent and controllable drug delivery in patients with neuropsychiatric conditions.
“Dosing the first patients in our Phase II study marks an important milestone in our clinical development programme of ELE-101 as we investigate its potential as an effective and rapid-acting intervention for depression,” Dr. Rob Conley, Beckley Psytech’s chief scientific and medical officer stated. “This study builds on the foundational work from …